Nanomaterial Technology and Triple Negative Breast Cancer
- PMID: 35096628
- PMCID: PMC8790081
- DOI: 10.3389/fonc.2021.828810
Nanomaterial Technology and Triple Negative Breast Cancer
Abstract
Triple negative breast cancer (TNBC) is a malignant breast cancer subtype that is prone to progression, with high associated metastasis and five-year mortality rates and an overall poor prognosis. Chemotherapy is usually administered to treat TNBC without additional targeted therapies. Novel nanomaterials have a variety of excellent physical and chemical properties and biological functions (including targeting specificity), and contrast agents and drug delivery vectors based on nanotechnology are progressing towards a more accurate and targeted direction. This review discusses the mechanisms of action and prospects for the use of nanotechnology in the treatment of TNBC, thus providing potential new strategies for the diagnosis and treatment of TNBC.
Keywords: drug delivery; nanobiosensors; nanomaterial; nanotechnology; triple negative breast cancer; vaccines.
Copyright © 2022 Hou, Ning, Chen and Wu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.Bioengineering (Basel). 2024 Aug 14;11(8):830. doi: 10.3390/bioengineering11080830. Bioengineering (Basel). 2024. PMID: 39199788 Free PMC article. Review.
-
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer.Int J Pharm. 2021 Aug 10;605:120835. doi: 10.1016/j.ijpharm.2021.120835. Epub 2021 Jun 28. Int J Pharm. 2021. PMID: 34197908 Review.
-
Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.J Proteomics. 2020 Feb 10;212:103581. doi: 10.1016/j.jprot.2019.103581. Epub 2019 Nov 12. J Proteomics. 2020. PMID: 31731051
-
Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer.Pharmacol Res. 2016 Sep;111:577-591. doi: 10.1016/j.phrs.2016.07.023. Epub 2016 Jul 25. Pharmacol Res. 2016. PMID: 27461138 Review.
-
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.Clin Epigenetics. 2018 Jun 27;10:88. doi: 10.1186/s13148-018-0514-z. eCollection 2018. Clin Epigenetics. 2018. PMID: 29983835 Free PMC article. Review.
Cited by
-
Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.Bioengineering (Basel). 2024 Aug 14;11(8):830. doi: 10.3390/bioengineering11080830. Bioengineering (Basel). 2024. PMID: 39199788 Free PMC article. Review.
-
Potential target and mechanism exploration from α-mangostin against triple-negative breast cancer: An in silico study.J Adv Pharm Technol Res. 2024 Jul-Sep;15(3):177-184. doi: 10.4103/JAPTR.JAPTR_49_24. Epub 2024 Jul 22. J Adv Pharm Technol Res. 2024. PMID: 39290544 Free PMC article.
-
Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.Front Oncol. 2022 May 26;12:907684. doi: 10.3389/fonc.2022.907684. eCollection 2022. Front Oncol. 2022. PMID: 35720010 Free PMC article. Review.
-
Natural biomass-derived carbon quantum dots: a path to antioxidant, anticancer, antibiofilm, and bacterial bioimaging potential.Mikrochim Acta. 2025 Apr 8;192(5):286. doi: 10.1007/s00604-025-07132-x. Mikrochim Acta. 2025. PMID: 40199801
-
Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.Int J Nanomedicine. 2024 Jun 18;19:6057-6084. doi: 10.2147/IJN.S453958. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38911501 Free PMC article.
References
-
- American Cancer Society Cancer Statistics 2021 Report. J Nucl Med (2021) 62(3):12N. - PubMed
Publication types
LinkOut - more resources
Full Text Sources